The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy

Abstract

BACKGROUND Both the 13-and 10-valent pneumococcal conjugate vaccines (PCV-13; PCV-10) are immunogenic and effective against vaccine-type pneumococcal disease when given to young children. However, limited data are available regarding the interchangeability of these 2 vaccines. METHODS UK children (n = 178) who had previously been vaccinated with PCV-13 at 2 and 4 months were randomized to receive either a PCV-13 or a PCV-10 booster at 12 months of age. PCV-13 vaccine-type antipolysaccharide serum immunoglobulin G (IgG) concentrations and opsonophagocytic assay titers were measured before and at 1 and 12 months following vaccination. The primary objective was to assess noninferiority of PCV-10 compared with PCV-13. RESULTS For 8 of the PCV-10 serotypes at least 97% of participants in both groups had IgG concentrations 0.35 µg/mL at 1 month after vaccination; inferior responses were seen for serotypes 5 and 9V following the PCV-10 compared with the PCV-13 booster. Post booster geometric mean IgG concentrations and opsonophagocytic assay titers were significantly superior for most serotypes in PCV-13 compared with PCV-10 recipients, whereas similar or inferior responses were seen for serotypes 4, 18C, and 19F. Although some increase in antibody was seen in PCV-10 recipients against the serotypes 6A and 19A (serotypes that cross-react with 6B and 19F in PCV-10, respectively) at 1-month post booster, these responses were significantly lower than in the PCV-13 group. CONCLUSIONS In PCV-13 primed infants, a PCV-10 booster is generally less immunogenic than a PCV-13 booster. For the 3 serotypes in PCV-10 with higher antigen content and/or conjugation to diphtheria or tetanus toxoid carrier proteins, higher or similar booster responses were seen in PCV-10 recipients. Although these findings suggest that responses are generally better with a PCV-13 booster among PCV-13 primed children, the clinical significance of these differences in immunogenicity is unclear. Vaccine RepoRtsBackground: Both the 13-and 10-valent pneumococcal conjugate vaccines (PCV-13; PCV-10) are immunogenic and effective against vaccine-type pneumococcal disease when given to young children. However, limited data are available regarding the interchangeability of these 2 vaccines. Methods: UK children (n = 178) who had previously been vaccinated with PCV-13 at 2 and 4 months were randomized to receive either a PCV-13 or a PCV-10 booster at 12 months of age. PCV-13 vaccine-type antipolysaccharide serum immunoglobulin G (IgG) concentrations and opsonophagocytic assay titers were measured before and at 1 and 12 months following vaccination. The primary objective was to assess noninferiority of PCV-10 compared with PCV-13. Results: For 8 of the PCV-10 serotypes at least 97% of participants in both groups had IgG concentrations ≥0.35 µg/mL at 1 month after vaccination;

Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia

“…One previous study has evaluated the interchangeability of PHiD-CV and PCV13 when given as booster doses in mixed schedules [14]. The study showed that a PHiD-CV booster is generally less immunogenic than a PCV13 booster in PCV13-primed children.…”

“…Although immunogenicity of both PHiD-CV and PCV13 has been compared to that of PCV7 [12,13], only a few studies have directly compared PHiD-CV and PCV13 [14][15][16]. In this study, we directly compared the immunogenicity and safety of PCV13 when administered as a booster dose in children primed with PHiD-CV or PCV13, either as a 2-or 3-dose schedule.…”

Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia

“…Several previous studies have indicated that PCV10 and PCV13 confer a comparable impact in pneumococcal disease overall [71][72][73]. Both products exhibit effectiveness and impact on overall disease and carriage.…”

Letter to the editor to: Isturiz et al. Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert review of vaccines 2017;16(10):1007-27

“…Isturiz et al [1] also note that mixed PCV dosing schedules have been evaluated, citing one study in which the immune responses to serotype 19A were initially higher for PCV13 primed children boosted with PCV13, versus PHiD-CV [30]. They also note that at 1 year post booster there was no significant difference in serotype 19A IgG concentrations between subjects in the two vaccine groups, but OPA titers remained significantly higher in the PCV13 group, demonstrating the variability inherent in using immunological measures as surrogates for expected impacts on disease.…”